Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
AssigneeFive Prime Therapeutics, Inc.
InventorsHaishan Lin, Li Long
Life of this patent
Estimating the term…
Abstract
The present invention relates to specific CSF1R ECD fusion molecules that exhibit improved therapeutic properties. The invention also relates to polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules. The invention also relates to methods of making and using the CSF1R ECD fusion molecules. The invention further relates to methods of treatment using the CSF1R ECD fusion molecules. For example, certain CSF1R ECDs of the invention may be used to treat rheumatoid arthritis (RA) or multiple sclerosis (MS).
Claims24
A colony stimulating factor 1 receptor (CSF1R) extracellular domain (ECD) fusion molecule comprising a CSF1R ECD and one or more fusion partners, wherein the amino acid sequence of the CSF1R ECD fusion molecule comprises SEQ ID NO.:2 and excludes the last six C-terminal amino acid residues of SEQ ID NO.:1.
A CSF1R ECD fusion molecule comprising a CSF1R ECD and an Fc, wherein the amino acid sequence of the CSF1R ECD fusion molecule comprises SEQ ID NO.:6.
A CSF1R ECD fusion molecule comprising a CSF1R ECD, an Fc, and polyethylene glycol, wherein the amino acid sequence of the CSF1 R ECD fusion molecule comprises SEQ ID NO.:6.
Dependencies are inferred from the claim text.